Key Highlights

  • The net loss was USD 25.8 million, or USD 0.20 per share, versus USD 18.0 million a year earlier.
  • Research and development expense rose 63% to USD 19.5 million, and total operating expenses reached USD 28.8 million.
  • Cash and cash equivalents were USD 187.7 million, which management believes funds operations through at least the end of 2028.
  • TibuSHIELD topline data in hidradenitis suppurativa are guided to the fourth quarter of 2026, with 247 participants enrolled.

Quarter Results

Zura Bio (NASDAQ:ZURA), a clinical-stage biotech company developing medicines for autoimmune and inflammatory diseases, filed its quarterly report for the period ended Sept. 30 on Tuesday. Total operating expenses were USD 28.8 million, compared with USD 19.5 million. Research and development expense rose 63%, or USD 7.5 million, to USD 19.5 million from USD 11.9 million, and general and administrative expense was USD 9.3 million versus USD 7.6 million.

Interest income was USD 1.8 million versus USD 1.5 million, and an income tax benefit of USD 1.2 million was recorded. The net loss was USD 25.8 million, or USD 0.20 per share, compared with USD 18.0 million for the prior-year quarter and a loss of USD 0.21 per share after accretion adjustments. Share-based compensation within general and administrative expense was USD 5.3 million versus USD 2.4 million.

Research and development detail shows tibulizumab spending of USD 3.9 million on the hidradenitis suppurativa program, USD 2.7 million on systemic sclerosis, USD 2.2 million on polymyalgia rheumatica and USD 5.0 million on general program costs. Wages and benefits in research and development were USD 3.6 million.

Nine-Month Results and Liquidity

For the nine months, total operating expenses were USD 83.6 million versus USD 56.8 million, and the net loss was USD 76.4 million, or USD 0.62 per share, versus USD 51.5 million, or USD 0.57. Net cash used in operating activities was USD 59.3 million versus USD 42.5 million. The company received net proceeds of USD 124.0 million from its February 2026 equity offering, after USD 8.5 million of underwriting fees.

Cash and cash equivalents were USD 187.7 million at Sept. 30. The company has raised aggregate gross proceeds of about USD 421.5 million and believes existing cash funds operating expenses and capital requirements through at least the end of 2028, while cautioning that it may use capital sooner than it currently anticipates.

Clinical Programs

Tibulizumab, a bispecific antibody designed to neutralize interleukin-17 and B-cell activating factor, is the lead candidate. TibuSHIELD, a Phase 2 study in moderate to severe hidradenitis suppurativa, completed enrollment with 247 participants against its initial target. Its primary endpoint is the percent change from baseline in abscess and inflammatory nodule count at week 16, and topline results are guided to the fourth quarter of 2026.

TibuSURE, a Phase 2 study in early diffuse cutaneous systemic sclerosis, enrolled 91 participants, with a change in modified Rodnan Skin Score as the primary endpoint and topline results guided to the first half of 2027. The FDA cleared an investigational new drug application for a Phase 2 study in polymyalgia rheumatica, with initiation planned for year end 2026. The company is also evaluating development and strategic options for tibulizumab and its other clinical-stage assets, including torudokimab, an interleukin-33 antibody, and crebankitug, an interleukin-7 receptor alpha antibody.

Autoimmune Pipeline Markers to Follow

Tracking points include TibuSHIELD topline data in the fourth quarter of 2026, TibuSURE results in the first half of 2027, and the start of the polymyalgia rheumatica study at year end. Further items are quarterly operating expense against USD 28.8 million, cash against USD 187.7 million, and any strategic decisions on the other clinical-stage assets.